{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:51:57Z","timestamp":1792212717755,"version":"4.4.0"},"reference-count":205,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jconrel.2022.09.031","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T17:36:45Z","timestamp":1663868205000},"page":"215-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":473,"special_numbering":"C","title":["Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products"],"prefix":"10.1016","volume":"351","author":[{"given":"Mohamed","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal E.","family":"Elsadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif E.","family":"Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Helmy","family":"Elgarhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal K.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.09.031_bb0005","first-page":"1257","article-title":"Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications","volume":"13","author":"D\u2019souza","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0010","article-title":"Refined exposure assessment of polyethylene glycol (E 1521) from its use as a food additive","volume":"16","author":"Younes","year":"2018","journal-title":"EFSA J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0015","first-page":"105","article-title":"Safety evaluation of polyethylene glycol (PEG) compounds for cosmetic use","volume":"31","author":"Jang","year":"2015","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0020","first-page":"1","article-title":"Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products","volume":"214","author":"Fruijtier-P\u00f6lloth","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0025","first-page":"1","article-title":"Recent applications of polyethylene glycols (PEGs) and PEG derivatives","volume":"2","author":"Hutanu","year":"2014","journal-title":"Mod. Chem. Appl"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0030","first-page":"1076","article-title":"Multimeric, multifunctional derivatives of poly (ethylene glycol)","volume":"3","author":"Zacchigna","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0035","first-page":"57","article-title":"In-vitro release of paracetamol from suppocire suppositories: role of additives, Malays","volume":"8","author":"Ranjita","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0040","first-page":"201","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0045","first-page":"3582","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0050","first-page":"214","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0055","series-title":"Polymer-Protein Conjugates","first-page":"103","article-title":"Immunological responses to PEGylated proteins: anti-PEG antibodies","author":"Elsadek","year":"2020"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0060","first-page":"104","article-title":"Immunogenicity of polyethylene glycol (PEG)","volume":"2","author":"Garay","year":"2011","journal-title":"Open Conf. Proc. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0065","first-page":"710","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0070","first-page":"1319","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0075","first-page":"1729","article-title":"The immunogenicity of polyethylene glycol: facts and fiction","volume":"30","author":"Schellekens","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0080","first-page":"1900170","article-title":"Immunogenicity of polyethylene glycol based nanomedicines: mechanisms, clinical implications and systematic approach","volume":"3","author":"d'Avanzo","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0085","first-page":"38","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0090","first-page":"56","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0095","first-page":"1071","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0100","first-page":"251","article-title":"Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0105","first-page":"2964","article-title":"Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice","volume":"17","author":"Elsadek","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0110","first-page":"467","article-title":"The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil\u00ae)","volume":"10","author":"Szebeni","year":"2000","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0115","first-page":"277","article-title":"PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability","volume":"36","author":"Verma","year":"2019","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0120","first-page":"766","article-title":"Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection\u2013a review","volume":"58","author":"Beaupin","year":"2017","journal-title":"J. Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0125","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children's Oncology Group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0130","first-page":"1761","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0135","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0140","first-page":"JC15","article-title":"The BNT162b2 (BioNTech\/Pfizer) vaccine had 95% efficacy against COVID-19\u2265 7 days after the 2nd dose","volume":"174","author":"Chagla","year":"2021"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0145","series-title":"Covid-19: Pfizer Vaccine Efficacy was 52% after First Dose and 95% after Second Dose, Paper Shows, in","author":"Mahase","year":"2020"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0150","first-page":"6486","article-title":"Safety and effectiveness of SARS-CoV-2 vaccines: a systematic review and meta-analysis","volume":"93","author":"Ling","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0155","first-page":"832","article-title":"PEG that reaction: a case series of allergy to polyethylene glycol","volume":"61","author":"Cox","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0160","first-page":"1101","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0165","first-page":"125","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine\u2014United States, December 21, 2020\u2013January 10, 2021","volume":"70","author":"C. COVID, R. Team","year":"2021","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0170","first-page":"861","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0175","first-page":"861","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0180","first-page":"e106","article-title":"Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?","volume":"126","author":"Garvey","year":"2021","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0185","first-page":"1617","article-title":"Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?","volume":"76","author":"Cabanillas","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0190","first-page":"907","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0195","first-page":"298","article-title":"The importance of poly (ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polym. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0200","first-page":"460","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0205","first-page":"445","article-title":"Surface modification of poly ethylene glycol to resist nonspecific adsorption of proteins","volume":"3","author":"Xiao","year":"2013","journal-title":"Chin. J. Anal. Chem."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0210","first-page":"346","article-title":"A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: An in vitro study of targeted delivery of cisplatin to ovarian cancer cells","volume":"117","author":"Bai","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0215","article-title":"Antibodies against polyethylene glycol in human blood: a literature review","volume":"102","author":"Hong","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0220","first-page":"325","article-title":"Physics, Laboratory synthesis of polyethylene glycol derivatives","volume":"25","author":"Harris","year":"1985","journal-title":"J. Macromol. Sci. Phys."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0225","first-page":"133","article-title":"Newly developed techniques on polycondensation, ring-opening polymerization and polymer modification: Focus on poly (lactic acid)","volume":"9","author":"Hu","year":"2016","journal-title":"J. Mater."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0230","series-title":"Algae Based Polymers, Blends, and Composites","first-page":"581","article-title":"Alginate-poly (ethylene) glycol and poly (ethylene) oxide blend materials","author":"Zia","year":"2017"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0235","first-page":"1935","article-title":"Beyond poly (ethylene glycol): linear polyglycerol as a multifunctional polyether for biomedical and pharmaceutical applications","volume":"15","author":"Thomas","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0240","first-page":"329","article-title":"Toxicity of topical polyethylene glycol","volume":"65","author":"Herold","year":"1982","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0245","first-page":"1342","article-title":"Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions","volume":"99","author":"Stylianopoulos","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0250","first-page":"247","article-title":"Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400): II Application to normal and abnormal permeability states in man and animals","volume":"73","author":"Chadwick","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0255","first-page":"305","article-title":"Peroral subchronic, chronic toxicity, and pharmacokinetic studies of a 100-KiIodaIton polymer of ethylene oxide (Polyox N-10) in the Fischer 344 Rat","volume":"19","author":"Leung","year":"2000","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0260","first-page":"169","article-title":"Tape stripping and sodium dodecyl sulfate treatment increase the molecular weight cutoff of polyethylene glycol penetration across murine skin","volume":"295","author":"Tsai","year":"2003","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0265","first-page":"73","article-title":"Oxidation of polyethylene glycols by alcohol dehydrogenase","volume":"38","author":"Herold","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0270","first-page":"521","article-title":"Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers","volume":"11","author":"Beranova","year":"1990","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0275","first-page":"349","article-title":"Fate of water-soluble polymers administered via different routes","volume":"84","author":"Yamaoka","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0280","first-page":"1261","article-title":"Pharmacokinetic and biodistribution properties of poly (ethylene glycol)\u2013protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0285","first-page":"2071","article-title":"Prodrug approaches for enhancing the bioavailability of drugs with low solubility","volume":"6","author":"Mueller","year":"2009","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0290","first-page":"36","article-title":"Solubility enhancement of Cox-2 inhibitors using various solvent systems","volume":"4","author":"Seedher","year":"2003","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0295","first-page":"221","article-title":"Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats","volume":"280","author":"Choi","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0300","first-page":"105","article-title":"PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery","volume":"13","author":"Milla","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0305","first-page":"531","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0310","first-page":"13","article-title":"Pegylation: engineering improved pharmaceuticals for enhanced therapy","volume":"28","author":"Molineux","year":"2002","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0315","first-page":"50","article-title":"Chemical and enzymatic site specific PEGylation of hGH: the stability and in vivo activity of PEG-N-terminal-hGH and PEG-Gln141-hGH conjugates","volume":"16","author":"Grigoletto","year":"2016","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0320","first-page":"67","article-title":"PEG\u2014a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0325","first-page":"6551","article-title":"In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice","volume":"9","author":"Gabizon","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0330","first-page":"257","article-title":"The enhanced permeability retention effect: a new paradigm for drug targeting in infection","volume":"68","author":"Azzopardi","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0335","article-title":"Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system","volume":"12","author":"Fukuda","year":"2017"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0340","first-page":"410","article-title":"PEGylated PLGA nanoparticles for the improved delivery of doxorubicin","volume":"5","author":"Park","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0345","first-page":"318","article-title":"Pegylated liposomal doxorubicin in the treatment of breast cancer","volume":"4","author":"O'Shaughnessy","year":"2003","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0350","first-page":"1029","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0355","first-page":"543","article-title":"Understanding biophysicochemical interactions at the nano\u2013bio interface","volume":"8","author":"Nel","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0360","first-page":"505","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0365","first-page":"323","article-title":"Identification of multiple cellular uptake pathways of polystyrene nanoparticles and factors affecting the uptake: relevance for drug delivery systems","volume":"93","author":"Firdessa","year":"2014","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0370","first-page":"35","article-title":"Immunogenicity risk assessment for PEGylated therapeutics","volume":"22","author":"Mora","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0375","first-page":"294","article-title":"Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS","volume":"6","author":"James","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0380","first-page":"1469","article-title":"Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary","volume":"7","author":"Markman","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0385","first-page":"78","article-title":"Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon \u03b1-2a (PEGASYS)","volume":"30","author":"Foser","year":"2003","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0390","first-page":"557","article-title":"Development of aptamer therapeutics","volume":"10","author":"Bunka","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0395","first-page":"444","article-title":"The enzyme as drug: application of enzymes as pharmaceuticals","volume":"14","author":"Vellard","year":"2003","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0400","first-page":"117","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0405","first-page":"389","article-title":"Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation","volume":"95","author":"Bukowski","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0410","first-page":"571","article-title":"Use of peginterferon alfa-2a (40 KD)(Pegasys\u00ae) for the treatment of hepatitis C","volume":"54","author":"Reddy","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0415","first-page":"75","article-title":"Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study","volume":"156","author":"Schreiber","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0420","first-page":"992","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials","volume":"113","author":"D\u2019Amico","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0425","first-page":"2931","article-title":"Anemia control in kidney transplant patients treated with methoxy polyethylene glycol-epoetin beta (mircera): the Anemiatrans Group","volume":"42","author":"Sanchez-Fructuoso","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0430","first-page":"1139","article-title":"Methoxy polyethylene glycol-epoetin beta","volume":"68","author":"Curran","year":"2008","journal-title":"ADIS Drug Evaluat."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0435","first-page":"1","article-title":"Certolizumab pegol (CIMZIA\u00ae) for the treatment of rheumatoid arthritis","volume":"14","author":"Connock","year":"2010","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0440","first-page":"1442","article-title":"FDA-approved poly (ethylene glycol)\u2013protein conjugate drugs","volume":"2","author":"Alconcel","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0445","first-page":"154","article-title":"FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia\u00ae; Rebinyn\u00ae)","volume":"25","author":"Ezban","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0450","first-page":"59","article-title":"Extended Half-life rFVIII for the treatment of hemophilia a: drugs consumption and patients\u2019 perspective, farmeconomia","volume":"21","author":"Roggeri","year":"2020","journal-title":"Health Econ. Ther. Pathways"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0455","first-page":"3193","article-title":"Improving the treatment of acute lymphoblastic leukemia","volume":"59","author":"Radadiya","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0460","first-page":"328","article-title":"FDA approval summary: calaspargase pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults","volume":"26","author":"Li","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0465","first-page":"391","article-title":"Pegvaliase: first global approval","volume":"32","author":"Markham","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0470","first-page":"156","article-title":"An overview of turoctocog alfa pegol (N8-GP; ESPEROCT\u00ae) assay performance: implications for postadministration monitoring","volume":"26","author":"Ezban","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0475","article-title":"Randomized, double-blind, cross-over phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references","volume":"30","author":"Velinova","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0480","first-page":"4291","article-title":"Pharmacokinetic and pharmacodynamic equivalence of pegfilgrastim-cbqv and pegfilgrastim in healthy subjects","volume":"37","author":"Finck","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0485","first-page":"665","article-title":"Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data","volume":"24","author":"Yang","year":"2021","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0490","first-page":"309","article-title":"Ropeginterferon alfa-2 b for the therapy of polycythemia vera","volume":"66","author":"\u010cervinek","year":"2020","journal-title":"Vnitr. Lek."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0495","first-page":"670","article-title":"PS1457 maintenance of response in long-term treatment with ropeginterferon alfA-2B (BESREMI\u00ae) VS. hydroxyurea in polycythemia vera patients (proud\/continuation-PV phase III trials)","volume":"3","author":"Gisslinger","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0500","first-page":"83","article-title":"Lonapegsomatropin: pediatric first approval","volume":"24","author":"Lamb","year":"2022","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0505","first-page":"1423","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0510","first-page":"798","article-title":"A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology","volume":"52","author":"Hu","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0515","first-page":"349","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0520","first-page":"3164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0525","article-title":"Pre-existing anti\u2013polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0530","first-page":"11804","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0535","first-page":"655","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0540","first-page":"129","article-title":"Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients","volume":"127","author":"Jakasa","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0545","first-page":"236","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0550","first-page":"124","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0555","first-page":"1","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"3","author":"Ichihara","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0560","first-page":"1336","article-title":"Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0565","first-page":"103","article-title":"Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0570","first-page":"1","article-title":"Therapy, Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0575","first-page":"1","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0580","first-page":"37","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0585","first-page":"167","article-title":"Accelerated clearance of a second injection of PEGylated liposomes in mice","volume":"255","author":"Ishida","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0590","first-page":"35","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0595","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0600","first-page":"56","article-title":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice","volume":"152","author":"Elsadek","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0605","first-page":"327","article-title":"Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice","volume":"334","author":"Emam","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0610","article-title":"A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes","volume":"615","author":"El Sayed","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0615","first-page":"163","article-title":"Anti-PEG antibodies: properties, formation and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0620","first-page":"27","article-title":"The chronic oral toxicology of thepolyethylene glycols*","volume":"44","author":"Smyth","year":"1955","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0625","first-page":"119","article-title":"Oral toxicity of polyethylene glycol (PEG 200) in monkeys and rats","volume":"2","author":"Prentice","year":"1978","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0630","first-page":"391","article-title":"A cautionary note: Toxicity of polyethylene glycol 200 injected intraperitoneally into mice","volume":"54","author":"Thiele","year":"2020","journal-title":"Lab. Anim."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0635","first-page":"18252","article-title":"Cytotoxicity study of polyethylene glycol derivatives","volume":"7","author":"Liu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0640","first-page":"324","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0645","first-page":"4274","article-title":"Classification of hypersensitivity reactions","volume":"40","author":"Dispenza","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0650","first-page":"341","article-title":"Anaphylaxis\u2014a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0655","series-title":"Classification of hypersensitivity reactions, in: Allergy and Asthma Proceedings","first-page":"S96","author":"Uzzaman","year":"2012"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0660","first-page":"683","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0665","first-page":"163","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0670","first-page":"9315","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0675","first-page":"1094","article-title":"Hypersensitivity reactions to intravenous lipid emulsion in swine: relevance for lipid resuscitation studies","volume":"119","author":"Bedocs","year":"2014","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0680","first-page":"40","article-title":"Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents","volume":"18","author":"Szebeni","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0685","first-page":"303","article-title":"Activation of serum complement by contrast media","volume":"11","author":"Lang","year":"1976","journal-title":"Investig. Radiol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0690","first-page":"25","article-title":"Hypersensitivity reactions to radiocontrast media: the role of complement activation","volume":"4","author":"Szebeni","year":"2004","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0695","first-page":"376","article-title":"A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid","volume":"67","author":"Border\u00e9","year":"2012","journal-title":"Contact Derm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0700","first-page":"216","article-title":"Polyethylene glycol (PEG)-induced anaphylactic reaction during bowel preparation","volume":"2","author":"Gachoka","year":"2015","journal-title":"ACG Case Rep. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0705","first-page":"1021","article-title":"Two cases of anaphylaxis to macrogol 6000 after ingestion of drug tablets","volume":"61","author":"Hyry","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0710","first-page":"443","article-title":"Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins","volume":"2","author":"Szebeni","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0715","first-page":"1945","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Des. Discov."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0720","first-page":"490","article-title":"Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs","volume":"468","author":"Szebeni","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0725","series-title":"Polymer-Protein Conjugates","first-page":"61","article-title":"PEG\u2013protein conjugates: nonclinical and clinical toxicity considerations","author":"Turecek","year":"2020"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0730","article-title":"To PEGylate or not to PEGylate: immunological properties of nanomedicine\u2019s most popular component, poly (ethylene) glycol and its alternatives","volume":"180","author":"Shi","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0735","first-page":"1","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol)(PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0740","first-page":"81","article-title":"cancer, Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic review","volume":"64","author":"Hasan","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0745","first-page":"103","article-title":"Clinical characteristics of intravenous PEG-asparaginase hypersensitivity reactions in patients undergoing treatment for acute lymphoblastic leukemia","volume":"35","author":"Browne","year":"2018","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0750","first-page":"366","article-title":"Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials","volume":"37","author":"Gupta","year":"2018","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0755","first-page":"1712","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0760","first-page":"890","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0765","first-page":"808","article-title":"Doxorubicin-induced hypersensitivity reactions, Drug Intell","volume":"18","author":"Solimando","year":"1984","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0770","first-page":"376","article-title":"Anaphylaxis to pegylated liposomal Doxorubicin: a case report","volume":"63","author":"Sharma","year":"2014","journal-title":"West Indian Med. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0775","first-page":"1020","article-title":"Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid","volume":"312","author":"Semple","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0780","first-page":"328","article-title":"Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0785","first-page":"616","article-title":"Lipid nanoparticle-mediated delivery of mRNA therapeutics and vaccines","volume":"27","author":"Swingle","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0790","article-title":"First full regulatory approval of a COVID-19 vaccine, the BNT162b2 Pfizer-BioNTech vaccine, and the real-world implications for public health policy","volume":"27","author":"Parums","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0795","article-title":"Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy","author":"Mahase","year":"2020","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0800","article-title":"Covid-19: UK approves Moderna vaccine to be given as two doses 28 days apart","author":"Mahase","year":"2021","journal-title":"British Med. J. British Med. J. Publish. Group"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0805","first-page":"1617","article-title":"Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?","volume":"76","author":"Cabanillas","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0810","first-page":"26","article-title":"Severe allergic reactions to the COVID-19 vaccine - statement and practical consequences","volume":"5","author":"Kleine-Tebbe","year":"2021","journal-title":"Allergol. Select"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0815","author":"CDC"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0820","first-page":"3308","article-title":"First-Dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0825","first-page":"670","article-title":"Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)","volume":"9","author":"Sellaturay","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0830","first-page":"322","article-title":"The role of complement in inflammation and phagocytosis","volume":"12","author":"Frank","year":"1991","journal-title":"Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0835","first-page":"479","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0840","first-page":"1020","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0845","first-page":"193","article-title":"Structure and function of the anaphylatoxins","volume":"7","author":"Hugh","year":"1984","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0850","first-page":"225","article-title":"Poly (ethylene glycol) s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process","volume":"46","author":"Hamad","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0855","first-page":"352","article-title":"Hypersensitivity to polyethylene glycols","volume":"53","author":"Shah","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0860","first-page":"542","article-title":"Macrogol hypersensitivity in multiple drug allergy","volume":"107","author":"Bommarito","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0865","first-page":"61","article-title":"Polyethylene glycols (PEG) and related structures: overlooked allergens in the perioperative setting","volume":"4","author":"Wenande","year":"2015","journal-title":"Case Rep."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0870","first-page":"1425","article-title":"Inhibition of polyethylene glycol\u2013induced histamine release by monomeric ethylene and diethylene glycol: a case of probable polyethylene glycol allergy","volume":"131","author":"Wenande","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0875","first-page":"478","article-title":"Usefulness of oral macrogol challenge in anaphylaxis after intra-articular injection of corticosteroid preparation","volume":"63","author":"Sohy","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0880","first-page":"176","article-title":"Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome","volume":"8","author":"Szebeni","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0885","first-page":"1931","article-title":"Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation","volume":"184","author":"Pedersen","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0890","first-page":"2","article-title":"Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses","volume":"195","author":"D\u00e9zsi","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0895","first-page":"409","article-title":"The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior","volume":"11","author":"Gao","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0900","first-page":"2779","article-title":"Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes","volume":"6","author":"Yallapu","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0905","first-page":"30","article-title":"The influence of lipid composition and surface charge on biodistribution of intact liposomes releasing from hydrogel-embedded vesicles","volume":"459","author":"Alinaghi","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0910","first-page":"107","article-title":"Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles","volume":"17","author":"Szebeni","year":"2007","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0915","first-page":"H1319","article-title":"Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction","volume":"279","author":"Szebeni","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0920","first-page":"477","article-title":"Role of complement activation in atherosclerosis","volume":"14","author":"Oksjoki","year":"2003","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0925","first-page":"1","article-title":"Effect of DOPE and cholesterol on the protein adsorption onto lipid nanoparticles","volume":"15","author":"Caracciolo","year":"2013","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0930","first-page":"1359","article-title":"Binding of plasma proteins to titanium dioxide nanotubes with different diameters","volume":"10","author":"Kulkarni","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0935","first-page":"3","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo","volume":"32","author":"Semple","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0940","first-page":"1704","article-title":"Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats","volume":"13","author":"Harashima","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0945","article-title":"Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0950","series-title":"Multiple Drug Allergy due to Hypersensitivity to Polyethylene Glycols of Various Molecular Weights","author":"Badiu","year":"2015"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0955","first-page":"1","article-title":"Anaphylaxis following a transvaginal ultrasound","volume":"12","author":"Jakubovic","year":"2016","journal-title":"Allergy, Asthma Clin. Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0960","first-page":"135","article-title":"Immediate and delayed allergic contact reactions to polyethylene glycol","volume":"4","author":"Fisher","year":"1978","journal-title":"Contact Derm."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0965","first-page":"2753","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0970","first-page":"601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncol. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb0975","first-page":"409","article-title":"Contact urticaria due to polyethylene glycol","volume":"19","author":"Fisher","year":"1977","journal-title":"Cutis"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0980","first-page":"509","article-title":"Increased absorption of polyethylene glycol 600 deposited in the colon in active ulcerative colitis","volume":"34","author":"Almer","year":"1993","journal-title":"GUT"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0985","first-page":"495","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0990","first-page":"567","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.09.031_bb0995","first-page":"474","article-title":"Delayed hypersensitivity reaction related to the use of pegfilgrastim","volume":"21","author":"Dadla","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jconrel.2022.09.031_bb1000","first-page":"908","article-title":"Polyethylene glycol: an underrecognized compound in certolizumab pegol and Movicol that may cause anaphylaxis","volume":"59","author":"McCabe","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jconrel.2022.09.031_bb1005","first-page":"427","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol, Pediatr. Blood","volume":"62","author":"Henriksen","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2022.09.031_bb1010","article-title":"Successful desensitization of Pegvaliase (Palynziq\u00ae) in a patient with phenylketonuria","volume":"23","author":"Patrawala","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.jconrel.2022.09.031_bb1015","first-page":"376","article-title":"Anaphylaxis to pegylated liposomal Doxorubicin: a case report","volume":"63","author":"Sharma","year":"2014","journal-title":"West Indian Med. J."},{"key":"10.1016\/j.jconrel.2022.09.031_bb1020","first-page":"512","article-title":"Vitreous injections of pegaptanib sodium triggering allergic reactions","volume":"143","author":"Steffensmeier","year":"2007","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2022.09.031_bb1025","first-page":"1712","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922006265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922006265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:29:47Z","timestamp":1759163387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922006265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":205,"alternative-id":["S0168365922006265"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.031","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}